NASDAQ:DVAX - Dynavax Technologies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$10.62 +0.13 (+1.24 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$10.49
Today's Range$10.39 - $10.98
52-Week Range$9.63 - $22.80
Volume759,300 shs
Average Volume1.33 million shs
Market Capitalization$729.73 million
P/E Ratio-6.14
Dividend YieldN/A
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:DVAX
Previous Symbol


Debt-to-Equity Ratio1.03
Current Ratio6.29
Quick Ratio5.90


Trailing P/E Ratio-6.14
Forward P/E Ratio-4.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$330,000.00
Price / Sales2,017.48
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.29 per share
Price / Book3.23


EPS (Most Recent Fiscal Year)($1.73)
Net Income$-95,150,000.00
Net Margins-5,044.85%
Return on Equity-97.79%
Return on Assets-57.24%


Outstanding Shares62,690,000
Market Cap$729.73 million

Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.08. The biopharmaceutical company had revenue of $1.46 million for the quarter, compared to the consensus estimate of $3.16 million. Dynavax Technologies had a negative return on equity of 97.79% and a negative net margin of 5,044.85%. Dynavax Technologies's revenue was up 2822.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.38) earnings per share. View Dynavax Technologies' Earnings History.

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Dynavax Technologies.

What price target have analysts set for DVAX?

4 brokers have issued 1-year target prices for Dynavax Technologies' shares. Their forecasts range from $25.00 to $32.00. On average, they expect Dynavax Technologies' share price to reach $28.00 in the next twelve months. This suggests a possible upside of 163.7% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

What is the consensus analysts' recommendation for Dynavax Technologies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

What are Wall Street analysts saying about Dynavax Technologies stock?

Here are some recent quotes from research analysts about Dynavax Technologies stock:
  • 1. According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (12/13/2018)
  • 2. Cantor Fitzgerald analysts commented, "Dynavax’s approved product, HEPLISAV-B, is a TLR9 agonist (1018 ISS) combined with recombinant Hepatitis surface Antigen (rHBsAg) used to vaccinate adults for the prophylaxis of HBV infection. When compared with existing vaccines, HEPLISAV-B has demonstrated higher protection in general patient groups and in high-risk patient populations, with a significantly more convenient dosing profile. HEPLISAV-B was approved on November 9, 2017." (10/19/2018)

Has Dynavax Technologies been receiving favorable news coverage?

Media headlines about DVAX stock have trended somewhat positive on Friday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Dynavax Technologies earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.

Are investors shorting Dynavax Technologies?

Dynavax Technologies saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 16,800,718 shares, an increase of 9.6% from the October 31st total of 15,327,587 shares. Based on an average trading volume of 1,209,271 shares, the short-interest ratio is currently 13.9 days. Approximately 27.1% of the shares of the stock are sold short. View Dynavax Technologies' Current Options Chain.

Who are some of Dynavax Technologies' key competitors?

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the folowing people:
  • Mr. Eddie Gray, CEO & Director (Age 59)
  • Dr. Dennis A. Carson Ph.D., M.D., Co-Founder, Director & Member of Scientific Advisory Board (Age 71)
  • Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 66)
  • Mr. David F. Novack, Sr. VP of Operations & Quality (Age 56)
  • Dr. Robert L. Coffman, Chief Scientific Officer & Sr. VP (Age 71)

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.59%), Franklin Resources Inc. (5.00%), HealthCor Management L.P. (4.98%), Vanguard Group Inc. (4.60%), Vanguard Group Inc (4.60%) and Senvest Management LLC (4.02%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach, Robert Coffman and Robert Janssen. View Institutional Ownership Trends for Dynavax Technologies.

Which institutional investors are selling Dynavax Technologies stock?

DVAX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., PointState Capital LP, C WorldWide Group Holding A S, TIAA CREF Investment Management LLC, FMR LLC, Credit Suisse AG, Federated Investors Inc. PA and Morgan Stanley. Company insiders that have sold Dynavax Technologies company stock in the last year include David F Novack, David Louis Johnson, Francis Cano and Michael S Ostrach. View Insider Buying and Selling for Dynavax Technologies.

Which institutional investors are buying Dynavax Technologies stock?

DVAX stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Clearbridge Investments LLC, HealthCor Management L.P., Panagora Asset Management Inc., Franklin Resources Inc., Senvest Management LLC, Bailard Inc. and Russell Investments Group Ltd.. View Insider Buying and Selling for Dynavax Technologies.

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $10.62.

How big of a company is Dynavax Technologies?

Dynavax Technologies has a market capitalization of $729.73 million and generates $330,000.00 in revenue each year. The biopharmaceutical company earns $-95,150,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. Dynavax Technologies employs 170 workers across the globe.

What is Dynavax Technologies' official website?

The official website for Dynavax Technologies is

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]

MarketBeat Community Rating for Dynavax Technologies (NASDAQ DVAX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  334 (Vote Outperform)
Underperform Votes:  318 (Vote Underperform)
Total Votes:  652
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel